imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
klacid 250 mg tabletti, kalvopäällysteinen
viatris oy - clarithromycin - tabletti, kalvopäällysteinen - 250 mg - klaritromysiini
klacid 500 mg tabletti, kalvopäällysteinen
viatris oy - clarithromycin - tabletti, kalvopäällysteinen - 500 mg - klaritromysiini
zeclar 250 mg tabletti, kalvopäällysteinen
orion corporation - clarithromycin - tabletti, kalvopäällysteinen - 250 mg - klaritromysiini
zeclar 500 mg tabletti, kalvopäällysteinen
orion corporation - clarithromycin - tabletti, kalvopäällysteinen - 500 mg - klaritromysiini
klacid od 500 mg säädellysti vapauttava tabletti
viatris oy - clarithromycin - säädellysti vapauttava tabletti - 500 mg - klaritromysiini
zeclar od 500 mg säädellysti vapauttava tabletti
orion corporation - clarithromycin - säädellysti vapauttava tabletti - 500 mg - klaritromysiini
klacid 50 mg/ml rakeet oraalisuspensiota varten
viatris oy - clarithromycin - rakeet oraalisuspensiota varten - 50 mg/ml - klaritromysiini
zeclar 50 mg/ml rakeet oraalisuspensiota varten
orion corporation - clarithromycin - rakeet oraalisuspensiota varten - 50 mg/ml - klaritromysiini
klacid 500 mg kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos
viatris oy - clarithromycin - kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos - 500 mg - klaritromysiini